论文部分内容阅读
目的对比融合重组质粒CSpcDNA3.1单独注射,与SpcDNA3.1+CpcDNA3.1联合注射的免疫效果。方法大量提取质粒后免疫小鼠,剂量为每次150μg,按0、2和4wk,共免疫3次。免疫后第1、3、5和7wk采血,用ELISA方法检测抗HBs和抗HCV抗体;用LDH法检测免疫小鼠脾细胞CTL的杀伤功能。结果无论从抗HBs和抗HCV抗体出现的时间、阳转率和应答强度,还是CTL水平,CSpcDNA3.1融合重组质粒都优于CpcD-NA3.1+SpcDNA3.1联合基因的免疫。结论融合DNA疫苗,有望成为慢性病毒性肝炎预防和治疗的制剂。
OBJECTIVE: To compare the immunogenicity of the recombinant plasmid CSpcDNA3.1 injected alone with SpcDNA3.1 + CpcDNA3.1. Methods Mice were immunized after a large number of plasmids were extracted and the dose was 150μg per injection. The mice were immunized three times at 0, 2 and 4 weeks. Blood was collected at 1, 3, 5 and 7wk after immunization. Anti-HBs and anti-HCV antibodies were detected by ELISA. CTL killing activity of splenocytes of immunized mice was detected by LDH. Results The CSpcDNA3.1 fusion plasmid was superior to the CpcD-NA3.1 + SpcDNA3.1 co-immunization in terms of time, anti-HBs and anti-HCV antibody appearance, positive rate and response intensity, and CTL level. Conclusions Fusion DNA vaccine is expected to become a preparation for the prevention and treatment of chronic viral hepatitis.